Cited by 70Additive Manufacturing and 3D Printing TechnologiesChemistry and Chemical EngineeringInnovative Microfluidic and Catalytic Techniques Innovation

The sustainability of emerging technologies for use in pharmaceutical manufacturing

Open access
Weaver, Edward, O’Hagan, Collette, Lamprou, Dimitrios A.·2022·Expert Opinion on Drug Delivery

Abstract

INTRODUCTION: Sustainability within the pharmaceutical industry is becoming a focal point for many companies, to improve the longevity and social perception of the industry. Both additive manufacturing (AM) and microfluidics (MFs) are continuously progressing, so are far from their optimization in terms of sustainability; hence, it is the aim of this review to highlight potential gaps alongside their beneficial features. Discussed throughout this review also will be an in-depth discussion on the environmental, legal, economic, and social particulars relating to these emerging technologies. AREAS COVERED: Additive manufacturing (AM) and microfluidics (MFs) are discussed in depth within this review, drawing from up-to-date literature relating to sustainability and circular economies. This applies to both technologies being utilized for therapeutic and analytical purposes within the pharmaceutical industry. EXPERT OPINION: It is the role of emerging technologies to be at the forefront of promoting a sustainable message by delivering plausible environmental standards whilst maintaining efficacy and economic viability. AM processes are highly customizable, allowing for their optimization in terms of sustainability, from reducing printing time to reducing material usage by removing supports. MFs too are supporting sustainability via reduced material wastage and providing a sustainable means for point of care analysis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/17425247.2022.2093857

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Production and manufacturing of medical products results in at least 15% of the industry's greenhouse gases.

    “Because the production and manufacturing of medical products results in at least 15% of the industry's GHGs, this is an important group to engage and mobilize.”

    From How Ophthalmologists Can Decarbonize Eye Care (2023) · cites this paper as [74]

    The Introduction says direct manufacturing is one source of the pharmaceutical industry's greenhouse-gas emissions. It does not quantify production and manufacturing of medical products as accounting for at least 15% of the industry's emissions; searches for that percentage found no supporting passage. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Masson-Delmotte V, 2018, IPCC Spec Rep Impacts Global Warming, 1, 49
  2. Gardan J, 2017, Addit Manuf Handb, 149
  3. Mianehro A, 2022, Carbohydr Polym Technol Appl, 3, 100187

Cited by

Sorted by citations

Authors
Weaver, E., O’Hagan, C., & Lamprou, D. A.
Affiliations
  • Queen's University Belfast (GB)
  • School of Pharmacy, Queen’s University Belfast, Belfast, UK
Corresponding author
Lamprou, Dimitrios A.
Venue
Expert Opinion on Drug Delivery
Published
2022-06-27
Volume
19
Issue
7
Pages
861-872
ISSN
  • 1742-5247 (ISSN-L)
  • 1744-7593
OpenAlex
W4283364899
Cited by
70
References
90
Citations by year
2026: 12 · 2025: 19 · 2024: 18 · 2023: 16 · 2022: 5
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • Expert Opinion on Drug Delivery (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (acceptedVersion, cc-by-nc-nd)
Topics
  • Physical Sciences › Engineering › Automotive Engineering › Additive Manufacturing and 3D Printing Technologies
  • Physical Sciences › Environmental Science › Environmental Chemistry › Chemistry and Chemical Engineering
  • Physical Sciences › Engineering › Biomedical Engineering › Innovative Microfluidic and Catalytic Techniques Innovation
Keywords
sustainability, pharmaceutical manufacturing, additive manufacturing, microfluidics, circular economy, environmental impact, point-of-care analysis, material waste reduction, economic feasibility
MeSH terms
Drug Industry, Pharmaceutical Preparations, Microfluidics, Printing, Three-Dimensional

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review